Retin Pharmaceuticals "Toluene Omarcycline" listing application to be included in the priority review

Developed by Paratek Pharmaceuticals, a pharmaceutical partner, toluene is a new type of tetracycline designed to overcome tetracycline resistance and has broad-spectrum antibacterial activity, including gramobacteria, gram-negative bacteria, atypical pathogens and a variety of drug-resistant strainsthe drug was available in the U.Sin February 2019 as a daily oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), known as NuzyraDrHarald Reinhart, Chief Medical Officer, Autoimmune and Anti-Infection,, said: "Toluene Omarcycline has broad-spectrum antibacterial activity and is highly active against drug-resistant strains, making it suitable for treatment in patients with CABP and ABSSSI in ChinaWith both intravenous infusion and oral prosdors, toluene omarlygcane can provide intravenous-oral sequence treatment options that can help patients significantly reduce the number of days in hospital and reduce the risk of infection in the hospitalAt present, China has limited treatment options for drug-resistant strains, and toluene omarlycin, as an innovative antibiotic drug, can address such unmet medical needs"